NEOGENOMICS INC 8-K

What Happened

• NeoGenomics, Inc. held its annual meeting on May 21, 2026 and filed an 8-K reporting the results. Stockholders approved a second amendment to the 2023 Equity Incentive Plan to add 5,000,000 shares authorized for issuance.
• Nine directors were re-elected to the board: Lynn A. Tetrault, Dr. Marjorie C. Green, Dr. Neil Gunn, Stephen M. Kanovsky, Michael A. Kelly, John P. Kenny, David B. Perez, Felicia Williams and Anthony P. Zook. A total of 116,630,120 shares were present or represented by proxy (≈89.61% of outstanding voting stock as of the March 23, 2026 record date).

Key Details

• Equity plan increase: 5,000,000 additional shares approved (Second Amendment to 2023 Equity Incentive Plan).
• Shareholder turnout: 116,630,120 shares voted or represented (~89.61% of outstanding voting stock).
• Advisory “say-on-pay”: approved with 91,781,833 votes in favor (≈83.19% of votes cast on the matter).
• Auditor ratification: Deloitte & Touche LLP was ratified as independent auditor with 116,103,093 votes in favor (≈99.57% of votes cast).

Why It Matters

• The 5 million share increase gives NeoGenomics additional shares to grant as stock-based compensation for employees, directors or executives, which can help retain and incentivize talent but may lead to dilution for existing shareholders as those awards vest or are exercised.
• Re-election of all nine directors and strong ratification of the auditor signal continuity in leadership and governance. The affirmative say-on-pay vote indicates broad shareholder support for the company’s executive compensation approach.